Emory University to Lead Infectious Diseases Clinical Research Consortium Leadership Group
The National Institute of Allergy and Infectious Diseases (NIAID) has selected Emory University to lead a new effort aimed at ...
Tag: NIAID
Center for Vaccine Development Awarded up to $201M to Establish Influenza Clinical Core
The Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) announced that ...
Senate Funding Bills Recognize, but Fall Short of Needs for Critical Infectious Disease Responses
The following statement released on Sept. 19 from the Infectious Diseases Society of America (IDSA) is published here in its ...
Radiation Nuclear Countermeasures Centralized Dosimetry Harmonization Effort
NIAID’s Radiation Nuclear Countermeasures Program (RNCP) seeks support to assess current methodology and variations in radiation dosing in in vivo and in vitro studies ...
CRADA Opportunity: Developing Protein Nanoparticles for the Display of Viral Epitopes
The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health seeks to partner with one ...
Whooping Cough: Tulane Awarded $8.5M to Develop Next-Generation Pertussis Vaccine
Tulane University researchers are developing a vaccine formulation that may provide longer lasting immunity in fewer doses against pertussis, more ...
First Human Trial of Live, Attenuated Zika Vaccine Begins
Vaccinations have begun in a first-in-human trial of an experimental Zika virus vaccine, the National Institute of Allergy and Infectious ...
Scientists Create 3D Structure of 1918 Influenza Virus-Like Particles
On the left is a 1918 H1 influenza virus-like particle (VLP) as seen by cryo-electron microscopy. On the right is ...
Submit Your Suggestions for the NIAID Tuberculosis Strategic Framework
The National Institute of Allergy and Infectious Diseases (NIAID) is developing a strategic framework to advance tuberculosis (TB) research and ...
MERS-CoV: Clinical Trial Starts for Regeneron’s Monoclonal Antibody Treatments
Enrollment has begun in an early-stage clinical trial testing the safety of two human monoclonal antibodies (mAbs) designed to treat ...
NIAID Backs Small-Molecule Radiation Modulator
Humanetics Corporation has been awarded a three-year contract valued at approximately $5.4 million from the National Institute of Allergy and ...
NIH Awards Contract for Management of Biocontainment Facility at Fort Detrick
The National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility (IRF) is part of the National Interagency Biodefense ...
NIAID Virology Quality Assurance Program
The National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS (DAIDS) is seeking proposals from qualified offerors to ...
Ebola Virus Can Infect Reproductive Organs of Macaques
Prior studies of survivors of the 2014-2016 Ebola outbreak in West Africa have revealed sexual transmission of Ebola virus, and that ...
NIAID Backs VesiculoVax Vaccine for Ebola, Marburg, and Lassa Viruses
Profectus BioSciences, Inc. has received a contract for up to $22.25 million from the National Institute of Allergy and Infectious ...
CRADA Opportunity: Evaluating Influenza Countermeasures in Healthy Volunteer Challenge Model
The high seasonal morbidity and mortality associated with both pandemic and seasonal influenza, the continued threat of highly pathogenic avian ...
NIAID Seeks Support Services for Infectious Diseases Research
The National Institute of Allergy and Infectious Diseases (NIAID) is competing a support contract for scientific, professional and technical expertise ...
MV-CHIKV Chikungunya Vaccine Clinical Trial Begins
A clinical trial of an experimental vaccine to prevent infection with chikungunya virus is now enrolling healthy adult volunteers at ...
Nonclinical Services for Development of Interventional Agents for Infectious Diseases
The National Institute of Allergy and Infectious Diseases (NIAID) Division of Microbiology and Infectious Diseases (DMID) is seeking proposals for ...
Advancing Therapeutic Discovery for Select Resistant Gram-Negative Bacteria
In response to the threat presented by increasing numbers of infections caused by antimicrobial–resistant (AR) and multidrug-resistant (MDR) Gram-negative bacterial ...
